Business
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL)Trial results did not meet the primary endpoint in the biomarker-selected populationTrial results did achieve statistical significance in the all-participants populationHighlights progress of promising product candidates:Positive preliminary data from Phase 1/2 trial of INO-3107 for the treatment of Recurrent Respiratory PapillomatosisPositive Phase 1b data for INO-4201 as Ebola booster for Ervebo® as primary seriesPositive data from a Phase 1/2 trial with INO-5401 in patients with glioblastomaUpdated results published for INO-3112, a product candidate being evaluated for the treatment of HPV-related cancersEnded 2022 with $253 million in cash, cash equivalents, and short-term investments and maintains cash runway projections to first quarter 2025Management will host conference call today at 4:30 p.m. ETPLYMOUTH MEETING, Pa., March 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today reported financial results for the quarter and year ended December 31, 2022, and provided a business update. INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update for the fourth quarter. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.\nINOVIO's President and Chief Executive Officer, Dr. Jacqueline Shea, said, \"The last year has been one of transition for INOVIO. We chose to make some difficult but essential decisions to best position our pipeline and organization for the future, and we are a stronger company because of it. We've honed our strategic vision, strengthened our financial position, and maintained our cash runway into first quarter 2025, enabling us to focus energy and resources on advancing candidates with scientific promise, achievable pathways to market, and strong commercial potential. Our continued commitment to financial discipline and operational excellence will guide us as we work to get those can...